Abstract A04: The tumor microenvironment is the main source of IL-6 for plasmacytoma development in mice.

Abstract

Abstract The development of targeted interventions for hematopoietic neoplasms of the B-lymphocyte lineage, such as multiple myeloma (MM), may benefit from preclinical experimental model systems in which complex interactions of neoplastic and nonmalignant bystander cells in the tumor microenvironment (TME) can be genetically dissected. Here we employ peritoneal plasmacytomagenesis in mice, which is strictly dependent on the pro-inflammatory cytokine, interleukine 6 (IL-6), to demonstrate that the nonmalignant bystanders are the main source of IL-6 for tumor development. B cell derived IL-6 is dispensable. The finding that lack of IL-6 in the TME significantly delays tumor onset in mice supports translational research efforts to target IL-6 production in bone marrow stroma cells for myeloma treatment and prevention. Citation Format: Timothy R. Rosean, Van S. Tompkins, Ramakrishna Sompallae, Lyse A. Norian, Herbert C. Morse, III, Thomas J. Waldschmidt, Siegfried Janz. The tumor microenvironment is the main source of IL-6 for plasmacytoma development in mice. [abstract]. In: Proceedings of the AACR Special Conference on Hematologic Malignancies: Translating Discoveries to Novel Therapies; Sep 20-23, 2014; Philadelphia, PA. Philadelphia (PA): AACR; Clin Cancer Res 2015;21(17 Suppl):Abstract nr A04.